Published in BMJ Open on January 24, 2014
Herpes simplex virus 2 infection: molecular association with HIV and novel microbicides to prevent disease. Med Microbiol Immunol (2014) 0.80
Herpes Simplex Virus Type-2 Cervicovaginal Shedding Among Women Living With HIV-1 and Receiving Antiretroviral Therapy in Burkina Faso: An 8-Year Longitudinal Study. J Infect Dis (2015) 0.76
Genital HSV Shedding among Kenyan Women Initiating Antiretroviral Therapy. PLoS One (2016) 0.75
Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med (2008) 13.72
Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med (1997) 7.59
The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J Acquir Immune Defic Syndr (2004) 5.94
Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Lancet (2010) 4.23
Performance of focus ELISA tests for herpes simplex virus type 1 (HSV-1) and HSV-2 antibodies among women in ten diverse geographical locations. Clin Microbiol Infect (2004) 3.27
Polymerase chain reaction for detection of herpes simplex virus (HSV) DNA on mucosal surfaces: comparison with HSV isolation in cell culture. J Infect Dis (2003) 3.19
Frequency of symptomatic and asymptomatic herpes simplex virus type 2 reactivations among human immunodeficiency virus-infected men. J Infect Dis (1998) 2.72
Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression. J Infect Dis (2002) 2.67
A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group. N Engl J Med (1999) 2.62
Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy. J Infect Dis (2011) 2.56
Importance of cytomegalovirus viraemia in risk of disease progression and death in HIV-infected patients receiving highly active antiretroviral therapy. Lancet (2004) 2.54
The frequency of unrecognized type 2 herpes simplex virus infection among women. Implications for the control of genital herpes. Sex Transm Dis (1990) 2.00
Effect of daily aciclovir on HIV disease progression in individuals in Rakai, Uganda, co-infected with HIV-1 and herpes simplex virus type 2: a randomised, double-blind placebo-controlled trial. Lancet Infect Dis (2012) 1.86
Increased genital shedding of herpes simplex virus type 2 in HIV-seropositive women. Ann Intern Med (1995) 1.70
Frequent reactivation of herpes simplex virus among HIV-1-infected patients treated with highly active antiretroviral therapy. J Infect Dis (2004) 1.65
Relationship between herpes simplex virus ulceration and CD4+ cell counts in patients with HIV infection. AIDS (1992) 1.56
Roles of clinical and subclinical reactivated herpes simplex virus type 2 infection and human immunodeficiency virus type 1 (HIV-1)-induced immunosuppression on genital and plasma HIV-1 levels. J Infect Dis (2008) 1.35
Performance of commercial herpes simplex virus type-2 antibody tests using serum samples from Sub-Saharan Africa: a systematic review and meta-analysis. Sex Transm Dis (2011) 1.29
Cervical shedding of herpes simplex virus in human immunodeficiency virus-infected women: effects of hormonal contraception, pregnancy, and vitamin A deficiency. J Infect Dis (2000) 1.18
Rapidly cleared episodes of oral and anogenital herpes simplex virus shedding in HIV-infected adults. J Acquir Immune Defic Syndr (2010) 1.16
Use of the designation "shedder" in mucosal detection of herpes simplex virus DNA involving repeated sampling. Sex Transm Infect (2009) 1.12
Herpes simplex virus infection in women in the WIHS: epidemiology and effect of antiretroviral therapy on clinical manifestations. AIDS (2006) 1.11
Coinfection with herpes simplex virus type 2 is associated with reduced HIV-specific T cell responses and systemic immune activation. J Infect Dis (2008) 1.11
Effect of HIV-1 and antiretroviral therapy on herpes simplex virus type 2: a prospective study in African women. Sex Transm Infect (2008) 1.08
Performance of the Focus HerpeSelect-2 enzyme immunoassay for the detection of herpes simplex virus type 2 antibodies in seven African countries. Sex Transm Infect (2011) 1.03
A randomized controlled pilot trial of valacyclovir for attenuating inflammation and immune activation in HIV/herpes simplex virus 2-coinfected adults on suppressive antiretroviral therapy. Clin Infect Dis (2013) 0.99
Left out but not forgotten: Should closer attention be paid to coinfection with herpes simplex virus type 1 and HIV? Can J Infect Dis Med Microbiol (2009) 0.85
Herpes simplex virus type 2, genital ulcers and HIV-1 disease progression in postpartum women. PLoS One (2011) 0.80
Herpes simplex virus type 2 coinfection does not accelerate CD4 count decline in untreated HIV infection. Clin Infect Dis (2013) 0.77
Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA (2003) 8.76
Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med (2008) 5.94
Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication. AIDS (2010) 3.26
Negative mucosal synergy between Herpes simplex type 2 and HIV in the female genital tract. AIDS (2007) 3.14
Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a correlate of HIV elite control. PLoS Pathog (2010) 2.99
Persistent HIV RNA shedding in semen despite effective antiretroviral therapy. AIDS (2009) 2.77
HIV-neutralizing immunoglobulin A and HIV-specific proliferation are independently associated with reduced HIV acquisition in Kenyan sex workers. AIDS (2008) 2.67
Identification of an innate T helper type 17 response to intestinal bacterial pathogens. Nat Med (2011) 2.48
Sexual risk factors for HIV infection in early and advanced HIV epidemics in sub-Saharan Africa: systematic overview of 68 epidemiological studies. PLoS One (2007) 2.44
The integrin alpha4beta7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1. Proc Natl Acad Sci U S A (2009) 2.30
Conflicting selective forces affect T cell receptor contacts in an immunodominant human immunodeficiency virus epitope. Nat Immunol (2006) 2.11
HIV-specific IL-21 producing CD4+ T cells are induced in acute and chronic progressive HIV infection and are associated with relative viral control. J Immunol (2010) 2.10
Cross-reactive cytotoxic T lymphocytes against a HIV-1 p24 epitope in slow progressors with B*57. AIDS (2002) 1.92
Intravaginal practices, bacterial vaginosis, and HIV infection in women: individual participant data meta-analysis. PLoS Med (2011) 1.89
Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr (2005) 1.87
Fertility desires and intentions of HIV-positive women of reproductive age in Ontario, Canada: a cross-sectional study. PLoS One (2009) 1.87
Increased HIV-specific CD8+ T-cell cytotoxic potential in HIV elite controllers is associated with T-bet expression. Blood (2011) 1.85
Illness in intensive care staff after brief exposure to severe acute respiratory syndrome. Emerg Infect Dis (2003) 1.76
Characterization of a human cervical CD4+ T cell subset coexpressing multiple markers of HIV susceptibility. J Immunol (2011) 1.67
Levels of innate immune factors in genital fluids: association of alpha defensins and LL-37 with genital infections and increased HIV acquisition. AIDS (2009) 1.64
Heterogeneity in host HIV susceptibility as a potential contributor to recent HIV prevalence declines in Africa. AIDS (2009) 1.63
HCV-specific T cells in HCV/HIV co-infection show elevated frequencies of dual Tim-3/PD-1 expression that correlate with liver disease progression. Eur J Immunol (2010) 1.60
Structures of three HIV-1 HLA-B*5703-peptide complexes and identification of related HLAs potentially associated with long-term nonprogression. J Immunol (2005) 1.60
Disproportionately high semen shedding of HIV is associated with compartmentalized cytomegalovirus reactivation. J Infect Dis (2005) 1.58
Recombination following superinfection by HIV-1. AIDS (2004) 1.57
Vitamin D and reduced risk of breast cancer: a population-based case-control study. Cancer Epidemiol Biomarkers Prev (2007) 1.55
Toll-like receptor expression and responsiveness are increased in viraemic HIV-1 infection. AIDS (2008) 1.55
Reduced mother-to-child transmission of HIV associated with infant but not maternal GB virus C infection. J Infect Dis (2008) 1.53
Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy-naive patients. J Infect Dis (2004) 1.52
Increased levels of immune activation in the genital tract of healthy young women from sub-Saharan Africa. AIDS (2010) 1.47
Immediate versus delayed polyalkylimide gel injections to correct facial lipoatrophy in HIV-positive patients. AIDS (2007) 1.47
Cross-clade HIV-1-specific neutralizing IgA in mucosal and systemic compartments of HIV-1-exposed, persistently seronegative subjects. J Acquir Immune Defic Syndr (2002) 1.45
Screening for HIV-specific T-cell responses using overlapping 15-mer peptide pools or optimized epitopes. AIDS (2004) 1.38
Associations of sexual risk taking among Kenyan female sex workers after enrollment in an HIV-1 prevention trial. J Acquir Immune Defic Syndr (2005) 1.37
Reduced rates of HIV acquisition during unprotected sex by Kenyan female sex workers predating population declines in HIV prevalence. AIDS (2008) 1.36
HIV-1 RNA dysregulates the natural TLR response to subclinical endotoxemia in Kenyan female sex-workers. PLoS One (2009) 1.35
Quality and quantity: mucosal CD4+ T cells and HIV susceptibility. Curr Opin HIV AIDS (2012) 1.29
Canadian consensus guidelines for the care of HIV-positive pregnant women: putting recommendations into practice. CMAJ (2003) 1.25
Sigmoid Th17 populations, the HIV latent reservoir, and microbial translocation in men on long-term antiretroviral therapy. AIDS (2011) 1.22
Mucosal innate immunity as a determinant of HIV susceptibility. Am J Reprod Immunol (2008) 1.22
No impact of oral tenofovir disoproxil fumarate on herpes simplex virus shedding in HIV-infected adults. AIDS (2011) 1.22
Elevated elafin/trappin-2 in the female genital tract is associated with protection against HIV acquisition. AIDS (2009) 1.21
Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial. Clin Infect Dis (2006) 1.20
Economic appraisal of Ontario's Universal Influenza Immunization Program: a cost-utility analysis. PLoS Med (2010) 1.19
Mucosal Th17 cell function is altered during HIV infection and is an independent predictor of systemic immune activation. J Immunol (2013) 1.18
Characterization of CD8 T-cell responses in HIV-1-exposed seronegative commercial sex workers from Nairobi, Kenya. Immunol Cell Biol (2006) 1.17
Bacterial vaginosis in HIV-infected women induces reversible alterations in the cervical immune environment. J Acquir Immune Defic Syndr (2008) 1.16
Effect of antiretroviral therapy on HIV reservoirs in elite controllers. J Infect Dis (2013) 1.15
High HIV risk in a cohort of male sex workers from Nairobi, Kenya. Sex Transm Infect (2013) 1.15
Better mind the gap: addressing the shortage of HIV-positive women in clinical trials. AIDS (2010) 1.14
Preferential apoptosis of HIV-1-specific CD4+ T cells. J Immunol (2005) 1.12
Coinfection with herpes simplex virus type 2 is associated with reduced HIV-specific T cell responses and systemic immune activation. J Infect Dis (2008) 1.11
Sustained changes in sexual behavior by female sex workers after completion of a randomized HIV prevention trial. J Acquir Immune Defic Syndr (2007) 1.10
Strong TCR conservation and altered T cell cross-reactivity characterize a B*57-restricted immune response in HIV-1 infection. J Immunol (2006) 1.09
HIV-specific CD8+ lymphocytes in semen are not associated with reduced HIV shedding. J Immunol (2005) 1.09
Clinical and immunogenetic correlates of abacavir hypersensitivity. AIDS (2005) 1.08
Tim-3 negatively regulates cytotoxicity in exhausted CD8+ T cells in HIV infection. PLoS One (2012) 1.07
Caring for women living with HIV: gaps in the evidence. J Int AIDS Soc (2013) 1.07
A CD4+ cell count <200 cells per cubic millimeter at 2 years after initiation of combination antiretroviral therapy is associated with increased mortality in HIV-infected individuals with viral suppression. J Acquir Immune Defic Syndr (2010) 1.05
Cervical HIV-specific IgA in a population of commercial sex workers correlates with repeated exposure but not resistance to HIV. AIDS Res Hum Retroviruses (2009) 1.03
Genital immunology and HIV susceptibility in young women. Am J Reprod Immunol (2012) 1.02
A randomized controlled pilot trial of valacyclovir for attenuating inflammation and immune activation in HIV/herpes simplex virus 2-coinfected adults on suppressive antiretroviral therapy. Clin Infect Dis (2013) 0.99
Association of vitamin D related information from a telephone interview with 25-hydroxyvitamin D. Cancer Epidemiol Biomarkers Prev (2008) 0.99
Otosyphilis in HIV-coinfected individuals: a case series from Toronto, Canada. AIDS Patient Care STDS (2008) 0.99
One-year outcomes and health care utilization in survivors of severe acute respiratory syndrome. Arch Intern Med (2007) 0.96
Blunted IL17/IL22 and pro-inflammatory cytokine responses in the genital tract and blood of HIV-exposed, seronegative female sex workers in Kenya. PLoS One (2012) 0.96
Gender and ethnicity differences in HIV-related stigma experienced by people living with HIV in Ontario, Canada. PLoS One (2012) 0.96
Ethnicity and gender differences in lipodystrophy of HIV-positive individuals taking antiretroviral therapy in Ontario, Canada. HIV Clin Trials (2011) 0.96
HIV-1 gp120 induces TLR2- and TLR4-mediated innate immune activation in human female genital epithelium. J Immunol (2013) 0.96
The effect of an education program on violence in the emergency department. Ann Emerg Med (2002) 0.95
A randomized trial of Raltegravir replacement for protease inhibitor or non-nucleoside reverse transcriptase inhibitor in HIV-infected women with lipohypertrophy. AIDS Patient Care STDS (2012) 0.94
Patterns of syphilis testing in a large cohort of HIV patients in Ontario, Canada, 2000-2009. BMC Infect Dis (2013) 0.94
Vitamin D from dietary intake and sunlight exposure and the risk of hormone-receptor-defined breast cancer. Am J Epidemiol (2008) 0.93
Vitamin D association with estradiol and progesterone in young women. Cancer Causes Control (2010) 0.93
Predictive value of HIV-1 protease genotype and virtual phenotype on the virological response to lopinavir/ritonavir-containing salvage regimens. Antivir Ther (2004) 0.92
Endometrial epithelial cell responses to coinfecting viral and bacterial pathogens in the genital tract can activate the HIV-1 LTR in an NF{kappa}B-and AP-1-dependent manner. J Infect Dis (2011) 0.92
Risk of cardiovascular disease associated with HCV and HBV coinfection among antiretroviral-treated HIV-infected individuals. Antivir Ther (2014) 0.92
HIV infection deregulates innate immunity to malaria despite combination antiretroviral therapy. AIDS (2013) 0.91
Feasibility and safety of cervical biopsy sampling for mucosal immune studies in female sex workers from Nairobi, Kenya. PLoS One (2012) 0.91
HIV infection deregulates Tim-3 expression on innate cells: combination antiretroviral therapy results in partial restoration. J Acquir Immune Defic Syndr (2013) 0.90
TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals. AIDS Patient Care STDS (2007) 0.90
Impact of asymptomatic Herpes simplex virus-2 infection on T cell phenotype and function in the foreskin. AIDS (2012) 0.89
HIV-specific T-cells accumulate in the liver in HCV/HIV co-infection. PLoS One (2008) 0.88
HLA typing in a Kenyan cohort identifies novel class I alleles that restrict cytotoxic T-cell responses to local HIV-1 clades. AIDS (2002) 0.88
Seroprevalence and risk factors for herpes simplex virus infection in a population of HIV-infected patients in Canada. Sex Transm Dis (2009) 0.88
Genital levels of soluble immune factors with anti-HIV activity may correlate with increased HIV susceptibility. AIDS (2008) 0.87
HIV-1 neutralizing activity is correlated with increased levels of chemokines in saliva of HIV-1-exposed uninfected individuals. Curr HIV Res (2008) 0.87
Effect of baseline HIV disease parameters on CD4+ T cell recovery after antiretroviral therapy initiation in Kenyan women. PLoS One (2010) 0.87
Stay it with flora: maintaining vaginal health as a possible avenue for prevention of human immunodeficiency virus acquisition. J Infect Dis (2008) 0.87
Vaccines in the public eye. Nat Med (2005) 0.87
Neisseria gonorrhoeae effectively blocks HIV-1 replication by eliciting a potent TLR9-dependent interferon-α response from plasmacytoid dendritic cells. Cell Microbiol (2010) 0.87
Treatment of HIV infection in pregnant women: antiretroviral management options. Drugs (2004) 0.86